Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Status: | Recruiting |
---|---|
Conditions: | Other Indications, Blood Cancer |
Therapuetic Areas: | Oncology, Other |
Healthy: | No |
Age Range: | 1 - 30 |
Updated: | 3/28/2019 |
Start Date: | December 8, 2014 |
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
This randomized phase III trial studies how well blinatumomab works compared with standard
combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that
has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab, may
induce changes in body's immune system and may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether standard combination chemotherapy is more
effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that
has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab, may
induce changes in body's immune system and may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether standard combination chemotherapy is more
effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
PRIMARY OBJECTIVES:
I. To compare disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR)
relapse B-cell acute lymphoblastic leukemia (B-ALL) patients who are randomized following
induction block 1 chemotherapy to receive either two intensive chemotherapy blocks or two
5-week blocks of blinatumomab (HR/IR randomization).
II. To compare the DFS of low risk (LR) relapse B-ALL patients who are randomized following
block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab
(LR randomization).
SECONDARY OBJECTIVES:
I. To compare overall survival (OS) of HR and IR relapse B-ALL patients who are randomized
following induction block 1 chemotherapy to receive either two intensive chemotherapy blocks
or two 5-week blocks of blinatumomab (HR/IR randomization).
II. To compare OS of LR relapse B-ALL patients who are randomized following block 1
chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR
randomization).
EXPLORATORY OBJECTIVES:
I. To compare the rates of minimal residual disease (MRD) >= 0.01% at the end of block 2 and
block 3 for HR and IR relapse B-ALL patients in HR/IR randomization.
II. To estimate, for treatment failure (TF) patients not previously receiving blinatumomab,
the hematologic complete remission rate (CR), rate of MRD < 0.01%, and proportion able to
proceed to hematopoietic stem cell transplant (HSCT) in CR after treatment with blinatumomab.
III. To assess the feasibility and safety of rapid taper of immune suppression for the subset
of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no acute graft versus host
disease (aGVHD).
IV. To evaluate blinatumomab pharmacokinetics (PK) and explore exposure-response
relationships for measures of safety and effectiveness.
OUTLINE:
All patients receive Block 1 over 4 weeks.
BLOCK 1: Patients receive dexamethasone orally (PO) twice daily (BID) or intravenously (IV)
on days 1-5 and 15-19; vincristine sulfate IV over 1 minute on days 1, 8, 15, and 22;
pegaspargase IV over 1-2 hours on days 3 and 17; and mitoxantrone hydrochloride IV over 15-30
minutes on days 1-2. Patients with central nervous system (CNS) 1 or CNS2 also receive
methotrexate intrathecally (IT) on days 1 and 8. Patients with CNS3 or isolated CNS relapse
also receive methotrexate IT, hydrocortisone IT, and cytarabine IT on days 1, 8, 15, and 22.
High risk and intermediate risk patients are then assigned to randomization R1. Low risk
patients are assigned to randomization R2.
RANDOMIZATION R1 (HR and IR patients): Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo
allogeneic HSCT.
ARM B: Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks,
and then undergo allogeneic HSCT.
RANDOMIZATION R2 (LR patients): Patients are then randomized to 1 of 2 treatment arms.
ARM C: Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8
weeks, Continuation 2 over 8 weeks, and then Maintenance.
ARM D: Patients receive Block 2 over 4 weeks, Blinatumomab Block 2 over 5 weeks, Continuation
1 over 8 weeks, Blinatumomab Block 3 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab
Block 3 over 5 weeks, and then Maintenance.
BLOCK 2: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine sulfate IV over
1 minute on day 1; methotrexate IV over 36 hours on day 8; leucovorin calcium IV or PO on
days 10-11; pegaspargase IV over 1-2 hours on day 9 or 10; cyclophosphamide IV over 15-30
minutes on days 15-19; and etoposide IV over 1-2 hours on days 15-19. Patients with CNS1 or
CNS2 also receive methotrexate IT on day 8. Patients with CNS3 also receive methotrexate IT,
hydrocortisone IT, and cytarabine IT on days 8 and 22.
BLOCK 3: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine sulfate IV over
1 minute on day 1; cytarabine IV over 3 hours every 12 hours on days 1, 2, 8, and 9;
asparaginase intramuscularly (IM) or IV over 1 hour on days 2, 4, 9, 11, and 23; methotrexate
IT on day 1 and IV over 36 hours on day 22; leucovorin calcium PO or IV on days 24-25.
Patients with CNS1 or CNS2 also receive methotrexate IT on day 22. Patients with CNS3 also
receive methotrexate IT, hydrocortisone IT, and cytarabine IT on day 22.
BLINATUMOMAB BLOCK 1: Patients dexamethasone PO or IV on day 1 and blinatumomab IV
continuously on days 1-28. Patients with CNS1 or CNS2 also receive methotrexate IT on days 15
and 29. Patients with CNS3 also receive methotrexate IT, hydrocortisone IT, and cytarabine IT
on days 15 and 29.
BLINATUMOMAB BLOCK 2: Patients blinatumomab IV continuously on days 1-28. Patients with CNS1
or CNS2 also receive methotrexate IT on days 8 and 29. Patients with CNS3 also receive
methotrexate IT, hydrocortisone IT, and cytarabine IT on days 8 and 29.
BLINATUMOMAB BLOCK 3: Patients blinatumomab IV continuously on days 1-28 and dexamethasone PO
or IV on day 1.
CONTINUATION 1 & 2: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine
sulfate IV over 1 minute on day 1; mercaptopurine tablet PO on days 1-42; methotrexate PO on
days 8, 15, 29, and 36; leucovorin calcium PO or IV on day 24-25 (patients with CNS1, CNS2,
or CNS3); cyclophosphamide IV over 15-30 minutes on days 43 and 50; etoposide IV over 1-2
hours on days 43 and 50; thioguanine PO once daily on days 43-49; and cytarabine IV over 1-30
minutes or subcutaneously (SC) on days 44-47 and 51-54. Patients with CNS1 or CNS2 also
receive methotrexate IT on days 1 and 43. Patients with CNS3 also receive methotrexate IT,
hydrocortisone IT, and cytarabine IT on days 1 and 43; methotrexate PO every 6 hours on day
22; and methotrexate IV over 36 hours on day 22.
MAINTENANCE: Patients receive dexamethasone PO BID or IV on days 1-5, 29-33, and 57-61;
vincristine sulfate IV over 1 minute on days 1, 29, and 57; mercaptopurine tablet PO on days
1-84; and methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Patients
with CNS1 or CNS2 also receive methotrexate IT on day 1. Patients with CNS3 also receive
methotrexate IT, hydrocortisone IT, and cytarabine IT on day 1. Cycles repeat every 12 weeks
for up to 2 years since the beginning of treatment in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up annually for 10 years.
I. To compare disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR)
relapse B-cell acute lymphoblastic leukemia (B-ALL) patients who are randomized following
induction block 1 chemotherapy to receive either two intensive chemotherapy blocks or two
5-week blocks of blinatumomab (HR/IR randomization).
II. To compare the DFS of low risk (LR) relapse B-ALL patients who are randomized following
block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab
(LR randomization).
SECONDARY OBJECTIVES:
I. To compare overall survival (OS) of HR and IR relapse B-ALL patients who are randomized
following induction block 1 chemotherapy to receive either two intensive chemotherapy blocks
or two 5-week blocks of blinatumomab (HR/IR randomization).
II. To compare OS of LR relapse B-ALL patients who are randomized following block 1
chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR
randomization).
EXPLORATORY OBJECTIVES:
I. To compare the rates of minimal residual disease (MRD) >= 0.01% at the end of block 2 and
block 3 for HR and IR relapse B-ALL patients in HR/IR randomization.
II. To estimate, for treatment failure (TF) patients not previously receiving blinatumomab,
the hematologic complete remission rate (CR), rate of MRD < 0.01%, and proportion able to
proceed to hematopoietic stem cell transplant (HSCT) in CR after treatment with blinatumomab.
III. To assess the feasibility and safety of rapid taper of immune suppression for the subset
of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no acute graft versus host
disease (aGVHD).
IV. To evaluate blinatumomab pharmacokinetics (PK) and explore exposure-response
relationships for measures of safety and effectiveness.
OUTLINE:
All patients receive Block 1 over 4 weeks.
BLOCK 1: Patients receive dexamethasone orally (PO) twice daily (BID) or intravenously (IV)
on days 1-5 and 15-19; vincristine sulfate IV over 1 minute on days 1, 8, 15, and 22;
pegaspargase IV over 1-2 hours on days 3 and 17; and mitoxantrone hydrochloride IV over 15-30
minutes on days 1-2. Patients with central nervous system (CNS) 1 or CNS2 also receive
methotrexate intrathecally (IT) on days 1 and 8. Patients with CNS3 or isolated CNS relapse
also receive methotrexate IT, hydrocortisone IT, and cytarabine IT on days 1, 8, 15, and 22.
High risk and intermediate risk patients are then assigned to randomization R1. Low risk
patients are assigned to randomization R2.
RANDOMIZATION R1 (HR and IR patients): Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo
allogeneic HSCT.
ARM B: Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks,
and then undergo allogeneic HSCT.
RANDOMIZATION R2 (LR patients): Patients are then randomized to 1 of 2 treatment arms.
ARM C: Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8
weeks, Continuation 2 over 8 weeks, and then Maintenance.
ARM D: Patients receive Block 2 over 4 weeks, Blinatumomab Block 2 over 5 weeks, Continuation
1 over 8 weeks, Blinatumomab Block 3 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab
Block 3 over 5 weeks, and then Maintenance.
BLOCK 2: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine sulfate IV over
1 minute on day 1; methotrexate IV over 36 hours on day 8; leucovorin calcium IV or PO on
days 10-11; pegaspargase IV over 1-2 hours on day 9 or 10; cyclophosphamide IV over 15-30
minutes on days 15-19; and etoposide IV over 1-2 hours on days 15-19. Patients with CNS1 or
CNS2 also receive methotrexate IT on day 8. Patients with CNS3 also receive methotrexate IT,
hydrocortisone IT, and cytarabine IT on days 8 and 22.
BLOCK 3: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine sulfate IV over
1 minute on day 1; cytarabine IV over 3 hours every 12 hours on days 1, 2, 8, and 9;
asparaginase intramuscularly (IM) or IV over 1 hour on days 2, 4, 9, 11, and 23; methotrexate
IT on day 1 and IV over 36 hours on day 22; leucovorin calcium PO or IV on days 24-25.
Patients with CNS1 or CNS2 also receive methotrexate IT on day 22. Patients with CNS3 also
receive methotrexate IT, hydrocortisone IT, and cytarabine IT on day 22.
BLINATUMOMAB BLOCK 1: Patients dexamethasone PO or IV on day 1 and blinatumomab IV
continuously on days 1-28. Patients with CNS1 or CNS2 also receive methotrexate IT on days 15
and 29. Patients with CNS3 also receive methotrexate IT, hydrocortisone IT, and cytarabine IT
on days 15 and 29.
BLINATUMOMAB BLOCK 2: Patients blinatumomab IV continuously on days 1-28. Patients with CNS1
or CNS2 also receive methotrexate IT on days 8 and 29. Patients with CNS3 also receive
methotrexate IT, hydrocortisone IT, and cytarabine IT on days 8 and 29.
BLINATUMOMAB BLOCK 3: Patients blinatumomab IV continuously on days 1-28 and dexamethasone PO
or IV on day 1.
CONTINUATION 1 & 2: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine
sulfate IV over 1 minute on day 1; mercaptopurine tablet PO on days 1-42; methotrexate PO on
days 8, 15, 29, and 36; leucovorin calcium PO or IV on day 24-25 (patients with CNS1, CNS2,
or CNS3); cyclophosphamide IV over 15-30 minutes on days 43 and 50; etoposide IV over 1-2
hours on days 43 and 50; thioguanine PO once daily on days 43-49; and cytarabine IV over 1-30
minutes or subcutaneously (SC) on days 44-47 and 51-54. Patients with CNS1 or CNS2 also
receive methotrexate IT on days 1 and 43. Patients with CNS3 also receive methotrexate IT,
hydrocortisone IT, and cytarabine IT on days 1 and 43; methotrexate PO every 6 hours on day
22; and methotrexate IV over 36 hours on day 22.
MAINTENANCE: Patients receive dexamethasone PO BID or IV on days 1-5, 29-33, and 57-61;
vincristine sulfate IV over 1 minute on days 1, 29, and 57; mercaptopurine tablet PO on days
1-84; and methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Patients
with CNS1 or CNS2 also receive methotrexate IT on day 1. Patients with CNS3 also receive
methotrexate IT, hydrocortisone IT, and cytarabine IT on day 1. Cycles repeat every 12 weeks
for up to 2 years since the beginning of treatment in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up annually for 10 years.
Inclusion Criteria:
- First relapse of B-ALL, allowable sites of disease include isolated bone marrow,
combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular;
extramedullary sites are limited to the CNS and testicles
- No waiting period for patients who relapse while receiving standard maintenance
therapy
- Patients who relapse on frontline therapy in phases other than maintenance must have
fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy,
or radiotherapy prior to entering this study
- Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with the
exception of hydroxyurea, which is permitted up to 24 hours prior to the start of
protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy
(methotrexate strongly preferred) administered at the time of the required diagnostic
lumbar puncture to establish baseline CNS status
- Biologic (anti-neoplastic) agent: at least 7 days since the completion of therapy with
a biologic agent; for agents that have known adverse events occurring beyond 7 days
after administration, this period must be extended beyond the time during which
adverse events are known to occur
- Stem cell transplant or rescue: patient has not had a prior stem cell transplant or
rescue
- Patient has not had prior treatment with blinatumomab
- With the exception of intrathecal chemotherapy (methotrexate strongly preferred;
cytarabine is permissible) administered at the time of the required diagnostic lumbar
puncture to establish baseline CNS status, patient has not received prior
relapse-directed therapy (i.e., this protocol is intended as the INITIAL treatment of
first relapse)
- Patients must have a performance status corresponding to Eastern Cooperative Oncology
Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and
Lansky for patients =< 16 years of age
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
- 1 to < 2 years: =< 0.6 mg/dL
- 2 to < 6 years: =< 0.8 mg/dL
- 6 to < 10 years: =< 1 mg/dL
- 10 to < 13 years: =< 1.2 mg/dL
- 13 to < 16 years: =< 1.5 mg/dL (males) and =< 1.4 mg/dL (females)
- >= 16 years: =< 1.7 mg/dL (males) and =< 1.4 mg/dL (females)
- Direct bilirubin < 3.0 mg/dL
- Shortening fraction of >= 27% by echocardiogram, or
- Ejection fraction of >= 50% by radionuclide angiogram
- All patients and/or their parent or legal guardian must sign a written informed
consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with Philadelphia chromosome positive/breakpoint cluster region protein
(BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL1)+ ALL are not eligible
- Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia are not eligible
- Patients with T-lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (T-LL) are not
eligible
- Patients with B-lymphoblastic lymphoma (B-LL) are not eligible
- Patients with known optic nerve and/or retinal involvement are not eligible; patients
who are presenting with visual disturbances should have an ophthalmologic exam and, if
indicated, a magnetic resonance imaging (MRI) to determine optic nerve or retinal
involvement
- Patients known to have one of the following concomitant genetic syndromes: Down
syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome,
Shwachman syndrome or any other known bone marrow failure syndrome
- Patients with known human immunodeficiency virus (HIV) infection
- Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and
etoposide phosphate (Etopophos)
- Lactating females who plan to breastfeed
- Patients who are pregnant since fetal toxicities and teratogenic effects have been
noted for several of the study drugs; a pregnancy test is required for female patients
of childbearing potential
- Sexually active patients of reproductive potential who have not agreed to use an
effective contraceptive method for the duration of their study participation
- Patients with pre-existing significant central nervous system pathology that would
preclude treatment with blinatumomab, including: history of severe brain injury,
dementia, cerebellar disease, organic brain syndrome, psychosis, coordination/movement
disorder, or autoimmune disease with CNS involvement are not eligible; patients with a
history of cerebrovascular ischemia/hemorrhage with residual deficits are not
eligible; (patients with a history of cerebrovascular ischemia/hemorrhage remain
eligible provided all neurologic deficits have resolved)
- Patients with uncontrolled seizure disorder are not eligible; (patients with seizure
disorders that do not require antiepileptic drugs, or are well controlled with stable
doses of antiepileptic drugs remain eligible)
We found this trial at
164
sites
Nashville, Tennessee 37203
Principal Investigator: Haydar A. Frangoul
Phone: 800-811-8480
Click here to add this to my saved trials
4900 Mueller Boulevard
Austin, Texas 78723
Austin, Texas 78723
(512) 324-0000
Principal Investigator: Amy C. Fowler
Phone: 214-648-7097
Dell Children's Medical Center of Central Texas Welcome to Dell Children
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Lydia A. Boateng
Phone: 484-884-2201
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Matthew A. Kutny
Phone: 205-934-0309
Children's Hospital of Alabama Children
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Clare J. Twist
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: William C. Petersen
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Cincinnati, Ohio 45229
1-513-636-4200
Principal Investigator: Maureen M. O'Brien
Phone: 513-636-2799
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 844-1000
Principal Investigator: John J. Letterio
Phone: 216-844-5437
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Mark A. Ranalli
Phone: 614-722-2708
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
Click here to add this to my saved trials
3533 South Alameda Street
Corpus Christi, Texas 78411
Corpus Christi, Texas 78411
(361) 694-5000
Principal Investigator: Nkechi I. Mba
Phone: 361-694-5311
Driscoll Children's Hospital Driscoll Children's Hospital was built because Clara Driscoll's will requested that a...
Click here to add this to my saved trials
7777 Forest Ln # C840
Dallas, Texas 75230
Dallas, Texas 75230
(972) 566-7000
Principal Investigator: Stanton C. Goldman
Phone: 972-566-5588
Medical City Dallas Hospital If you have concerns for your health, that of a family...
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
Duarte, California 91010
(626) 256-4673
Principal Investigator: Anna B. Pawlowska
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Marshall A. Schorin
Phone: 703-208-6650
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Michael S. Isakoff
Phone: 800-579-7822
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Anderson (Andy) B. Collier
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
Los Angeles, California 90027
(323) 660-2450
Principal Investigator: Leo Mascarenhas
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Fataneh (Fae) Majlessipour
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
4015 22nd Place
Lubbock, Texas 79410
Lubbock, Texas 79410
806-725-0000
Principal Investigator: Kishor M. Bhende
Phone: 806-775-8590
Covenant Children's Hospital Every child is different. And when they're sick or injured, they deserve...
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
Norfolk, Virginia 23507
(757) 668-7000
Principal Investigator: Eric J. Lowe
Phone: 757-668-7243
Children's Hospital of The King's Daughters Children
Click here to add this to my saved trials
747 52nd St
Oakland, California 94609
Oakland, California 94609
(510) 428-3000
Principal Investigator: Carla B. Golden
Phone: 510-450-7600
Children's Hospital and Research Center Oakland For nearly 100 years, Children's Hospital & Research Center...
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
Orange, California 92868
(714) 997-3000
Principal Investigator: Elyssa M. Rubin
Phone: 714-997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
Click here to add this to my saved trials
5153 North 9th Avenue
Pensacola, Florida 32504
Pensacola, Florida 32504
(850) 505-4700
Principal Investigator: Evangeline J. Brown
Phone: 904-697-3529
Nemours Children's Clinic - Pensacola Nemours Children’s Clinic, Pensacola serves children and families in northwest...
Click here to add this to my saved trials
530 Northeast Glen Oak Avenue
Peoria, Illinois 61603
Peoria, Illinois 61603
(309) 624-4945
Principal Investigator: Jaime M. Libes
Phone: 888-226-4343
Saint Jude Midwest Affiliate The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic was...
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
215-590-1000
Principal Investigator: Susan R. Rheingold
Phone: 215-590-2810
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Arthur K. Ritchey
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Bill H. Chang
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Jennifer J. Greene Welch
Phone: 401-444-1488
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Christina M. Wiedl
Phone: 804-628-1939
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Angela R. Girvin
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
7700 Floyd Curl Dr
San Antonio, Texas 78229
San Antonio, Texas 78229
(210) 575-7000
Principal Investigator: Vinod K. Gidvani-Diaz
Phone: 210-575-7000
Methodist Children's Hospital of South Texas Methodist Children
Click here to add this to my saved trials
3020 Childrens way
San Diego, California 92123
San Diego, California 92123
(858) 576-1700
Principal Investigator: William D. Roberts
Phone: 858-966-5934
Rady Children's Hospital - San Diego Rady Children's Hospital-San Diego is the region’s pediatric medical...
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Juan F. Rico
Phone: 813-844-7829
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
Click here to add this to my saved trials
40 Sunshine Cottage Road
Valhalla, New York 10595
Valhalla, New York 10595
(914) 594-4000
Principal Investigator: Jessica C. Hochberg
Phone: 914-594-3794
New York Medical College The College was founded in 1860 by a group of New...
Click here to add this to my saved trials
1600 Rockland Road
Wilmington, Delaware 19803
Wilmington, Delaware 19803
(302) 651-4200
Principal Investigator: Emi H. Caywood
Phone: 302-651-6884
Alfred I. duPont Hospital for Children Nemours began more than 70 years ago with the...
Click here to add this to my saved trials
Akron, Ohio 44308
Principal Investigator: Steven J. Kuerbitz
Phone: 330-543-3193
Click here to add this to my saved trials
Albany, New York 12208
Principal Investigator: Kenneth G. Lucas
Phone: 518-262-5513
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Felipe S. Bautista-Otanez
Phone: 734-712-3671
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Brenda J. Wittman
Phone: 907-212-6871
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Rajen Mody
Phone: 800-865-1125
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Douglas J. Scothorn
Phone: 828-213-4150
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Glen Lew
Phone: 404-785-1112
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Kelly W. Maloney
Phone: 720-777-6672
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Teresa A. York
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Patrick A. Brown
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Jason M. Fixler
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Nadine P. SantaCruz
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Kenneth Lieuw
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Eugenia Chang
Phone: 208-381-3376
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boston, Massachusetts 02111
Principal Investigator: Michael J. Kelly
Phone: 617-636-5535
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Lisa Gennarini
Phone: 718-379-6866
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Stuart H. Gold
Phone: 877-668-0683
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Jacqueline M. Kraveka
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Charleston, West Virginia 25304
Principal Investigator: Ashley E. Meyer
Phone: 304-388-9944
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Joel A. Kaplan
Phone: 800-804-9376
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Jessica A. Bell
Phone: 704-384-5369
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Principal Investigator: Manoo G. Bhakta
Phone: 865-331-1812
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Nobuko Hijiya
Phone: 773-880-4562
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: Mary L. Schmidt
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Jennifer L. McNeer
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Rabi Hanna
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Tamra L. Slone
Phone: 214-648-7097
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Jagadeesh Ramdas
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Dayton, Ohio 45404
Principal Investigator: Ayman A. El-Sheikh
Phone: 800-228-4055
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jennifer J. Clark
Phone: 866-775-6246
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Meret Henry
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
Detroit, Michigan 48236
Principal Investigator: Adonis N. Lorenzana
Phone: 734-712-3671
Click here to add this to my saved trials
9333 Imperial Highway
Downey, California 90242
Downey, California 90242
Principal Investigator: Robert M. Cooper
Phone: 510-891-3400
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Susan G. Kreissman
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
East Lansing, Michigan 48824
Principal Investigator: Aghiad Chamdin
Phone: 517-975-9547
Click here to add this to my saved trials
El Paso, Texas 79905
Principal Investigator: Lisa L. Hartman
Phone: 915-298-5444
Click here to add this to my saved trials
1600 S Andrews Ave
Fort Lauderdale, Florida 33316
Fort Lauderdale, Florida 33316
(954) 355-4400
Principal Investigator: Hector M. Rodriguez-Cortes
Phone: 954-355-5346
Broward Health Medical Center Broward Health, providing service for more than 75 years, is a...
Click here to add this to my saved trials
Fort Myers, Florida 33908
Principal Investigator: Emad K. Salman
Phone: 877-680-0008
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
Fort Worth, Texas 76104
(682) 885-4000
Principal Investigator: Kenneth M. Heym
Phone: 682-885-2103
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Gainesville, Florida 32610
Principal Investigator: William B. Slayton
Phone: 352-273-8010
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54301
Principal Investigator: Catherine A. Long
Phone: 920-433-8889
Click here to add this to my saved trials
1001 E 5th St
Greenville, North Carolina 27858
Greenville, North Carolina 27858
(252) 328-6131
Principal Investigator: Andrea R. Whitfield
Phone: 252-744-1015
East Carolina University Whether it's meeting the demand for more teachers and healthcare professionals or...
Click here to add this to my saved trials
900 West Faris Rd.
Greenville, South Carolina 29605
Greenville, South Carolina 29605
(864)455-8898
Principal Investigator: Nichole L. Bryant
Phone: 864-241-6251
BI-LO Charities Children's Cancer Center The BI-LO Charities Children
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Burton E. Appel
Phone: 201-996-2879
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
Hollywood, Florida 33021
Principal Investigator: Iftikhar Hanif
Phone: 954-265-2234
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
Honolulu, Hawaii 96826
(808) 983-6000
Principal Investigator: Wade T. Kyono
Phone: 808-983-6090
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Terzah M. Horton
Phone: 713-798-1354
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: Kamnesh R. Pradhan
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Principal Investigator: Bassem I. Razzouk
Phone: 317-338-2194
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Emi H. Caywood
Phone: 904-697-3529
Click here to add this to my saved trials
Kansas City, Missouri 64108
Principal Investigator: Keith J. August
Click here to add this to my saved trials
2018 W Clinch Ave
Knoxville, Tennessee 37916
Knoxville, Tennessee 37916
(865) 541-8000
Principal Investigator: Ray C. Pais
Phone: 865-541-8266
East Tennessee Children's Hospital East Tennessee Children's Hospital is a not-for-profit, private, independent pediatric medical...
Click here to add this to my saved trials
Las Vegas, Nevada 89109
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89144
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89135
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
Lebanon, New Hampshire 03756
(603) 650-5000
Principal Investigator: Julie Kim
Phone: 800-639-6918
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
Lexington, Kentucky
Principal Investigator: Vlad C. Radulescu
Phone: 859-257-3379
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: David L. Becton
Phone: 501-686-8274
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
Click here to add this to my saved trials
11234 Anderson St
Loma Linda, California 92354
Loma Linda, California 92354
(909) 558-4000
Principal Investigator: Albert Kheradpour
Phone: 909-558-3375
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
Click here to add this to my saved trials
Long Beach, California 90806
Principal Investigator: Pamela H. Kempert
Phone: 562-933-5600
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: William A. May
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Ashok B. Raj
Phone: 866-530-5516
Click here to add this to my saved trials
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
Principal Investigator: Michelle A. Manalang
Phone: 800-782-8581
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
Maywood, Illinois 60153
(888) 584-7888
Principal Investigator: Eugene Suh
Phone: 708-226-4357
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
Click here to add this to my saved trials